Stopping GLP-1 Drugs Erases Cardiovascular Protection, Raising Heart Risk by 22% After Two Years

Stopping GLP-1 medications like Ozempic and Wegovy rapidly erases the cardiovascular protection patients accumulate while taking them, increasing the risk of a major heart event by up to 22% after two years. A comprehensive 2026 study of 333,687 U.S. veterans with type 2 diabetes demonstrates that the heart-protective benefits of these drugs depend entirely on continuous use, with even short interruptions causing a measurable decline in cardiovascular defense.[1][5]

The mechanism behind this loss of protection involves what researchers term a "metabolic whiplash." GLP-1 receptor agonists do more than suppress appetite; they actively reduce systemic inflammation, lower blood pressure, and improve cholesterol profiles. When the medication is withdrawn, these underlying metabolic markers rebound. While weight regain is the most visible consequence of stopping the drug, the invisible resurgence of cardiovascular risk factors poses a far more immediate threat to heart health.[2][5]

Researchers at the Washington University School of Medicine in St. Louis tracked the veteran cohort over a three-year period, comparing 132,551 patients prescribed GLP-1 medications against 201,136 patients taking sulfonylureas, an older class of diabetes drugs. They assessed each patient's treatment status every six months. The scale of the data provides one of the clearest pictures to date of how these drugs perform in real-world settings outside tightly controlled clinical trials.[2][4]

The findings, published in the journal BMJ Medicine, quantify the exact cost of interrupting therapy. Patients who maintained continuous GLP-1 treatment throughout the three-year study achieved an 18% lower risk of major cardiovascular events—defined as heart attacks, strokes, or death—compared to the sulfonylurea group. This translates to roughly four fewer major cardiovascular events per 100 people over the study period.[3][5]

However, the data shows that walking away from the medication quickly dismantles that defense. Approximately 26% of the GLP-1 users in the study stopped taking the drugs completely, while another 23% experienced a treatment gap of at least six months. For those who paused their medication for just six months, cardiovascular risk increased by 4% to 8% compared to continuous users.[1][5]

The longer patients remained off the medication, the steeper the climb in risk. After one full year without GLP-1 therapy, patients faced a 14% higher risk of suffering a major cardiovascular event. By the two-year mark, that risk shot up to 22%, effectively wiping out the cardiovascular advantages gained during the treatment period.[3][4]

"There is enormous exuberance about starting GLP-1 drugs, but not nearly enough attention to what happens when people stop," said Dr. Ziyad Al-Aly, a clinical epidemiologist at Washington University and senior author of the study. "Many quit after a few months because of cost, side effects or shortages. When they stop, it's not just weight that comes back; they experience a resurgence in inflammation, blood pressure, and cholesterol."[5]

Restarting the medication after a break offered only a partial rescue. Patients who resumed GLP-1 therapy after an interruption achieved an average 12% reduction in cardiovascular risk, falling short of the 18% reduction seen in those who never stopped. "Our data suggest this metabolic whiplash is detrimental to heart health," Dr. Al-Aly noted. "Restarting the medication helped restore some protection, but only partially, showing that discontinuation leaves a lasting scar."[2][5]

What remains unproven is whether this exact risk trajectory applies equally to patients taking GLP-1 drugs strictly for weight loss rather than type 2 diabetes management. Because the Washington University cohort consisted entirely of veterans diagnosed with diabetes, the baseline cardiovascular risk was already elevated. Researchers have yet to determine if younger, non-diabetic patients experience the same rapid loss of heart protection when they cycle off the medication.[4][5]

The findings arrive as roughly one in eight American adults now takes a GLP-1 drug, with high discontinuation rates driven by out-of-pocket costs that can exceed $1,000 a month and persistent supply chain shortages. The data shifts the medical consensus on how these drugs should be prescribed, framing them not as temporary interventions for weight loss, but as long-term maintenance therapies for cardiovascular and metabolic health.[4][5]